Navigation Links
Helix BioPharma Corp. Announces Fiscal 2008 Results
Date:10/28/2008

d to Topical Interferon Alpha-2b reflect additional costs in preparation to open additional sites in Germany for the AGW clinical trial and the expected Phase IIb/III IND/CTA filings for LSIL to occur before the end of the Company's fiscal fourth quarter ending July 31, 2009.

Operating, general and administration expenses in fiscal 2008 totaled $4,757,000 and represent an increase of $339,000 or 7.7% when compared to fiscal 2007. Operating, general and administration expenses reflect higher audit and consulting fees and a one time charge of $434,000 relating to the resignation of the Company's Chairman. Offsetting these cost were lower marketing promotional costs and legal fees associated with the 2008 Annual General Meeting.

Amortization of intangible assets in fiscal 2008 totaled $16,000 and represented a decrease of $143,000 when compared to fiscal 2007. Certain intangible assets were fully amortized in fiscal 2007 and prior, resulting in the lower amortization expense in fiscal 2008 and on a go forward basis. Amortization of capital assets in fiscal 2008 decreased marginally when compared to fiscal 2007.

Stock-based compensation expense in fiscal 2008 totaled $44,000 and represents a decrease of $3,000 when compared to fiscal 2007. The Company did not issue any stock options in fiscal 2008 and the stock-based compensation expense during the year represents the ongoing amortization of compensation costs of stock options granted on June 30, 2005, over their vesting period.

Interest income totaled $645,000 in fiscal 2008 and $496,000 in 2007. The increase is mainly the result of higher on hand cash balances in fiscal 2008 versus fiscal 2007.

The Company realized a foreign exchange gain of $327,000 in fiscal 2008, which compares favorably to the foreign exchange gain of $9,000 which was realized in fiscal 2007. The Canadian dollar's strength over the last three fiscal years has moderated in fiscal 2008 and was range bound while the
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma Closes $11.4 Million Private Placement
2. Helix BioPharma Announces $11.4 Million Private Placement
3. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
4. Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
5. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
6. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
7. Helix BioPharma reports Q2 2008 highlights, financial results
8. Helix BioPharma shareholders vote in favour of management
9. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Helix BioPharma announces Q1 2008 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... SAN FRANCISCO, Calif., Feb. 28 ,Exelixis, Inc. (Nasdaq: ... director of investor relations, will present at the,Susquehanna SIGnificant ... a.m. PT on Tuesday, March 4, 2008., The ... the Event,Calendar page under Investors on the Exelixis website ...
... /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.,(NASDAQ: AEZS , ... therapy and oncology, will announce its fourth quarter ... open on,Wednesday, March 5, 2008. The Company will ... results later that same day at 10:00 a.m., ...
... InterMune, Inc.,(Nasdaq: ITMN ) today announced ... InterMune, will present at Susquehanna,s Second Annual,SIGnificant Options ... 5, 2008,at 2:30 p.m. EST., To access ... and other,interested parties may log on to the ...
Cached Biology Technology:InterMune to Present at the SIGnificant Options in Healthcare Conference 2
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:12/3/2014)... IRVINE, Calif. , Dec. 2, 2014 /PRNewswire/ ... of globally deployed, innovative test solutions for military, ... the newest version of its successful TS-900 ... the performance and features of high-end systems to ... with outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... obesity has nearly tripled in the past three decades, and ... were classified as obese. If actions against childhood obesity do ... be the first generation in over a century to experience ... childhood obesity which leads to complications in later life. While ...
... is developing virtual models of human knee joints to ... to heavy loads virtual models that someday can ... aging process or by debilitating diseases, such as osteoarthritis. ... leveraging the powerful computing systems of the Ohio Supercomputer ...
... in immune system cells and epithelial cells (such as skin ... these peptides, human neutrophil peptide 1, under certain circumstances hinders ... HIV entry into mature T-helper cells (cells essential ... to specific targets on T-helper cells, uptake of the virus, ...
Cached Biology News:To understand childhood obesity, researchers look to inactive, fat rats 2To understand childhood obesity, researchers look to inactive, fat rats 3Researchers study knee stress at tissue, cellular levels 2Under the right conditions, peptide blocks HIV infection at multiple points along the way 2